Protocol Ledger

NCT03836352 · Phase II · ACTIVE NOT RECRUITING

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Interventional Phase II clinical trial protocol NCT03836352 sponsored by ImmunoVaccine Technologies, Inc. (IMV Inc.) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-12-21 Enrollment: 184 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT03836352
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)184 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03836352
Protocol FieldVerified Registry Value
NCT IdentifierNCT03836352
Consolidated Lead SponsorImmunoVaccine Technologies, Inc. (IMV Inc.)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment184 participants (ESTIMATED)
Registered Start Date2018-12-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03836352
Hospital Research SiteLocationSite Profile
Cedars-Sinai Medical CenterLos Angeles, CAOpen Hospital Dossier ->
Emory Winship Cancer InstituteAtlanta, GAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI